Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALMOTRIPTAN MALATE vs ALPELISIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ALMOTRIPTAN MALATE vs ALPELISIB: Safety Overview

Metric ALMOTRIPTAN MALATE ALPELISIB
Total FAERS Reports 497 8,419
Deaths Reported 3 1,271
Death Rate 0.6% 15.1%
Hospitalizations 60 1,705
Average Patient Age 52.4 yrs 58.8 yrs
% Female Patients 16.5% 94.7%
FDA Approval Date Jul 7, 2015 Apr 24, 2024
Manufacturer Mylan Pharmaceuticals Inc. Novartis Pharmaceuticals Corporation
Route ORAL ORAL
Marketing Status Discontinued Prescription